Dermal fillers are marketed as temporary. Hyaluronic acid products carry duration claims of 6 to 18 months, depending on the formulation and injection site. Patients are told the gel gradually dissolves and is absorbed by the body. The marketing is not exactly wrong — the visible cosmetic effect does fade. But the filler material itself does not always leave when the brochure says it does.
MRI and ultrasound studies published between 2022 and 2025 have repeatedly shown hyaluronic acid filler persisting in facial tissues for 2 to 15 years after injection. This is not a fringe finding from a single center. It has been replicated across multiple imaging modalities, patient populations, and filler brands. None of the major manufacturers advertise this. Most injectors were not taught it. And most patients have no idea.
This does not mean filler is inherently dangerous. For most patients who receive conservative amounts from qualified injectors, long-term residual filler remains clinically silent. But for patients who have accumulated large volumes over many years, the consequences can include visible migration, tissue distortion, delayed granulomas, chronic swelling, and a face that no longer responds to additional filler in the expected way.
Understanding what actually happens to filler over time — and what the imaging shows — is the starting point for making better decisions about whether to continue, pause, or reverse.
What MRI and ultrasound actually show
The most striking evidence comes from a 2024 study published in Plastic and Reconstructive Surgery — Global Open that reviewed MRI scans of 33 patients who had received hyaluronic acid filler in the midface. Every single patient showed residual HA on MRI. Among them, 21 had not been injected for 2 to 5 years, and 12 had not been injected for 5 to 15 years. The study reported HA longevity of up to 15 years across different products, with high inter-rater reliability between two blinded radiologists (84.47% agreement).
A separate case report in PMC documented a patient with confirmed residual HA filler on MRI 2.5 years after injection — not as a cosmetic concern, but because the filler had become a reservoir for a recurrent bacterial infection that was refractory to antibiotics until the filler was dissolved.
A 2022 long-term MRI follow-up study found HA persistence in the lateral face and deep fat compartments of the midface at 19 months, with near-complete degradation in the chin. The takeaway: filler duration is site-dependent. Areas with less movement and denser tissue (midface, temples) retain filler longer than high-mobility zones (lips, chin).
A narrative review of filler migration published in MDPI reported cases of filler migration presenting anywhere from 2 weeks to 60 years after injection. The extreme-late-presentation cases were overwhelmingly associated with permanent fillers (silicone, polyalkylimide, PMMA, polyacrylamide), but at least one case documented HA filler migration presenting 16 years post-injection.
An ultrasound study of 57 patients with permanent facial fillers found lymphatic spread to cervical lymph nodes in 34 patients (59.6%), many of whom had no clinical symptoms. MRI in the same review detected significantly more filler deposits than were suspected on clinical examination alone.
Why filler persists beyond advertised duration
Several factors explain the gap between manufacturer duration claims and imaging reality:
Cross-linking density. Hyaluronic acid fillers are chemically cross-linked to slow degradation. The more cross-links (BDDE, DVS, or PEG cross-linkers, depending on the product), the more resistant the gel is to the body's natural hyaluronidase enzyme. Vycross technology (Allergan/AbbVie), for example, uses a mix of high- and low-molecular-weight HA with high cross-linking density. These products are designed for longevity — and they deliver it, sometimes beyond what was intended.
Injection site. Static areas (cheeks, temples, tear troughs) metabolize filler more slowly than dynamic areas (lips, perioral lines). Deep placement in fat compartments is also associated with slower degradation than superficial dermal placement.
Cumulative volume. Patients who receive repeated injections over years accumulate residual product. Even if each session adds a small amount, the total volume of cross-linked HA sitting in the tissue grows. Imaging studies consistently show that patients with the highest cumulative exposure have the most residual filler on MRI.
Individual metabolism. Baseline hyaluronidase activity varies between individuals. There is no reliable way to predict how quickly a specific patient will break down filler.
Migration: how filler moves and where it goes
Filler migration is the displacement of injected material from its intended location to adjacent tissue planes. It is one of the most discussed and most misunderstood long-term risks.
Migration can occur through several mechanisms:
- Mechanical displacement. Repeated injection into the same area creates pressure that pushes existing filler into surrounding tissue. This is most common in the lips (the "filler mustache" — filler migrating above the vermillion border) and the nasolabial folds.
- Gravitational drift. Over years, filler in the midface can drift inferiorly with tissue laxity, contributing to jowling or heaviness in the lower face.
- Lymphatic spread. The ultrasound and MRI literature documents filler particles in cervical lymph nodes years after facial injection. This is more common with permanent fillers but has been observed with HA as well.
- Vascular spread. In the setting of intravascular injection (whether recognized at the time or not), filler particles can embolize to distant sites.
A 2017 Korean radiology study evaluated 39 patients with filler-related symptoms and found that the most common presentation was a palpable mass or mass migration (54% of symptomatic patients). The time between injection and imaging ranged from 3 weeks to 21 years.
Granulomas and delayed inflammatory reactions
Foreign-body granulomas are late-onset nodules that develop months to years after filler injection. They result from chronic inflammatory reactions to residual foreign material in the tissue. Histologically, they show modified macrophages (epithelioid cells), lymphocytes, and attempts at encapsulation.
Key facts:
- Granulomas and delayed inflammatory reactions to HA fillers occur in approximately 0.3% of patients.
- Onset ranges from 2 weeks to 6 years after injection.
- They are more common with heavily cross-linked products and permanent fillers.
- They can be triggered or exacerbated by immune stimulation — multiple case series document granuloma flare-ups after COVID-19 vaccination or infection, thought to result from immune reactivation against previously dormant filler biofilms.
- The Vycross cross-linking technology has been associated with higher rates of delayed inflammatory nodules compared to NASHA or XpresHA technologies, though the absolute numbers remain low.
A 2022 review in PMC noted that the COVID-19 pandemic brought a wave of delayed filler complications, with granulomas presenting months after vaccination in patients who had been injected years earlier. The pathogenesis is thought to involve T-cell-mediated immune reactivation rather than new filler reactions.
Tissue stretch and the overfilled face
The question of whether fillers stretch the skin permanently is one patients ask frequently. The honest answer is nuanced.
Appropriate volumes of filler, injected conservatively, do not cause meaningful tissue stretch. The skin and subcutaneous tissue have enough elasticity to accommodate small-volume augmentation and return to baseline when the filler degrades.
The problem arises with chronic over-volumization. When large amounts of filler are placed repeatedly over years, the tissue expands beyond its elastic limit. As one plastic surgeon quoted in Allure described it: "In extreme and prolonged cases of filler use, the face can never go back to what it was," because the gel has damaged and aged the tissues. In these cases, dissolving the filler can leave stretched tissues unsupported, causing areas of the face to collapse and appear darker.
This is the core dilemma of the "overfilled face": removing the filler reveals tissue damage that the filler was masking. Treatment in these cases often requires a combination approach — partial filler dissolution, surgical correction of laxity, and regenerative treatments like nanofat grafting or PRP to help restore tissue quality.
What the FDA has said
The FDA's executive summary for the General and Plastic Surgery Devices Advisory Committee panel meeting on dermal fillers (prepared August 2025) highlighted several long-term concerns:
- Dermal fillers can cause granulomas, lumps, and nodules that occur weeks to years after injection.
- Migration of dermal filler has been "long described" in the literature.
- Filler in the décolletage area can interfere with breast cancer screening and other diagnostic imaging, with the FDA noting that palpable filler nodules or granulomas could be mistaken for suspicious breast masses during clinical examination.
- Cervical lymph node enlargement due to complications from facial fillers injected years prior has been reported.
The FDA's labeling now includes warnings about intravascular injection, vision impairment, blindness, stroke, and skin necrosis. It does not currently mandate duration labeling based on MRI persistence data.
Who is at risk and who is not
Not every patient with filler needs to worry about these outcomes. The risk profile breaks down roughly as follows:
Lower risk:
- Patients who have received small total volumes (under 3–5 mL cumulative)
- Patients treated conservatively by board-certified dermatologists or plastic surgeons
- Patients with no history of delayed swelling, nodules, or inflammatory reactions
- Patients who space treatments appropriately and reassess before each session
Higher risk:
- Patients who have received large cumulative volumes (10+ mL over years)
- Patients treated at high-volume med spas with aggressive dosing protocols
- Patients with a history of delayed inflammatory reactions or granulomas
- Patients who have received permanent or semi-permanent fillers (PMMA, polyalkylimide, silicone)
- Patients with autoimmune conditions or a history of severe allergic reactions
Surgical implications: what happens at facelift
Plastic surgeons who operate on patients with extensive filler histories report that residual filler alters tissue planes, obscures anatomical landmarks, and complicates dissection. The filler creates fibrotic tissue and inflammatory changes that make the normal surgical anatomy harder to identify. In some cases, filler deposits must be physically removed during surgery.
For patients considering facelift or blepharoplasty after years of filler, the recommended approach is:
- Dissolve residual HA filler several weeks before surgery (ideally with ultrasound guidance) to restore normal tissue planes.
- Allow 4–6 weeks for inflammation from hyaluronidase to settle before the surgical date.
- Inform the surgeon of your complete filler history — products, approximate volumes, dates, and any complications.
What to do if you have had filler for years
If you are asymptomatic and happy with your appearance: No action is needed. Residual filler on MRI is not inherently dangerous. The important thing is to inform any future injector about your treatment history and cumulative volume so they can plan accordingly.
If you are experiencing swelling, lumps, or distortion: See a board-certified dermatologist or plastic surgeon who uses diagnostic ultrasound. Ultrasound can identify residual filler deposits, distinguish them from other tissue changes, and guide hyaluronidase dissolution if HA filler is present. Blind injection of dissolver without imaging guidance risks missing deposits and over-dissolving in the wrong areas.
If you want to reverse years of filler: Expect a staged process. Complete dissolution is rarely achievable in a single session, especially after years of cumulative product. Your provider may recommend multiple sessions of ultrasound-guided hyaluronidase, spaced weeks apart, with clinical reassessment between sessions. In cases where tissue laxity has developed, surgical referral for blepharoplasty or facelift may be more appropriate than continued filler correction.
If you are planning surgery after years of filler: Inform your surgeon about your complete filler history, including products, approximate volumes, and dates. Residual filler can alter tissue planes, affect surgical outcomes, and interfere with postoperative imaging.
Questions to ask before your next filler appointment
- How much total filler volume have I received over the last several years?
- Have you reassessed my facial anatomy from scratch, or are you planning to add to what is already there?
- Do you use ultrasound to evaluate existing filler before injecting more?
- What is the plan if I develop delayed swelling or nodules months from now?
- Is the amount you are recommending consistent with what you would inject into your own face?
Sources
- Master M, Roberts S. Long-term MRI follow-up of hyaluronic acid dermal filler. Plast Reconstr Surg Glob Open. 2022;10:e4252. https://pmc.ncbi.nlm.nih.gov/articles/PMC9007185/
- Hyaluronic acid filler longevity in the mid-face: a review of 33 magnetic resonance imaging studies. PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11250456/
- Hyaluronic acid fillers may be longer-lasting than previously described: a case report of delayed filler-associated facial cellulitis. PMC. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9198373/
- Long-term persistence of hyaluronic acid fillers: a clinical illustration and implications for practice. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC13100341/
- Filler migration after facial injection — a narrative review. MDPI Cosmetics. 2023;10(4):115. https://www.mdpi.com/2079-9284/10/4/115
- Are delayed dermal filler granulomas more common since COVID-19? PMC. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9507785/
- Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers. PMC. 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2686337/
- FDA Executive Summary: General Issues Panel Meeting on Dermal Fillers. August 2025. https://www.fda.gov/media/188185/download
- Management of delayed complications of hyaluronic acid fillers: case series from the Middle East. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12011065/
- Managing complications of fillers: rare and not-so-rare. PMC. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4728901/
